Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.

Leukemia research - 1 Feb 2010

Breccia Massimo, Alimena Giuliana

Abstract excerpt

Imatinib mesylate is currently the standard of care for chronic myeloid leukemia (CML) patients in early chronic phase. However, the emergence of resistance and intolerance has dampened the enthusiasm for this drug. To overcome this phenomenon, different strategies have been developed, including novel targeted agents. Nilotinib, formerly known as AMN107, is a second-generation tyrosine kinase inhibitor 30-fold...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Treatment Outcome

Source

Identifiers

PMID: 19783301
DOI: 10.1016/j.leukres.2009.08.031

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.PMID 19783301Read ↗

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read ↗

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Semantic proximity Read ↗

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.Semantic proximity Read ↗

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation.Semantic proximity Read ↗

Second line small molecule therapy options for treating chronic myeloid leukemia.Semantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.